Health & Environmental Research Online (HERO)


Print Feedback Export to File
3370853 
Journal Article 
Calcipotriene and betamethasone dipropionate for the topical treatment of plaque psoriasis 
Kin, KC; Hill, D; Feldman, SR 
2016 
Yes 
Expert Review of Clinical Pharmacology
ISSN: 1751-2433 
9 
6 
789-797 
WOS:000377130400006 
Introduction: Psoriasis affects an estimated 2% of the world's population, with higher rates in developed countries. 80% have mild-to-moderate disease and 50 to 80% have scalp involvement. Topical treatments are the mainstay of treatment.Areas covered: Two-compound calcipotriene and betamethasone dipropionate (BD) is a common topical combination therapy consisting of a vitamin D analogue and a corticosteroid. It comes in ointment, gel/suspension, and foam formulations. Phase II and III clinical trials have consistently shown the two-compound formulation to be effective and safe, with no clinically significant skin atrophy, calcium level changes, or adrenal suppression were seen. Topical scalp solution was also safe and effective in treating scalp psoriasis in pediatric populations.Expert commentary: Calcipotriene plus BD is more effective and safer than the individual ingredients in the same vehicle for treating body and scalp psoriasis. It should be considered a first line therapy for mild-to-moderate plaque psoriasis. 
Psoriasis; calcipotriene; betamethasone dipropionate; topical